RxDoctor Payments Data

Kristopher Steinke, MD

Psychiatry · San Antonio, TXNPI 1558375642

Payments from drug & device makers

$3,304in general payments, 2019–2025

Across 159 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$555
  • Otsuka America Pharmaceutical, Inc.$440
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$358
  • AbbVie$241
  • Lundbeck LLC$204
  • plus $489 from 7 others

What the payments were for

  • Food & beverage$3,25799%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,304 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$4,850
Medicare patients
12
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate19$58,799
Risperdal ConstaRisperidone Microspheres13$33,002
Lisdexamfetamine Dimesylate28$6,238
VyvanseLisdexamfetamine Dimesylate16$5,740
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl12$1,237
Duloxetine Hcl42$926
Mirtazapine73$838
Quetiapine Fumarate41$810
Venlafaxine Hcl ErVenlafaxine Hcl26$799
Buspirone Hcl43$781
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine25$676
Methylphenidate Hcl24$621
Hydroxyzine Pamoate34$610
Divalproex Sodium ErDivalproex Sodium21$592
Risperidone67$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$167$91,80132 claims
Almatica Pharma LLCSertraline Hcl$26$49152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →